Steve Bryson, PhD, science writer —

Janssen Pharmaceuticals is seeking European Union approval for talquetamab, a subcutaneous (under-the-skin) antibody therapy for hard-to-treat multiple myeloma. The request, in the…

A CAR T-cell therapy called CART-ddBCMA that targets the protein BCMA — produced at high levels in myeloma cells — safely led to lasting…

Adding Ninlaro (ixazomib) to cyclophosphamide and dexamethasone does not improve progression-free survival for multiple myeloma patients who relapsed after several lines of treatment,…

Carvykti (ciltacabtagene autoleucel; cilta-cel) has been recommended for approval in Europe by the Committee for Medicinal Products for Human Use (CHMP), an arm of the…

Black people with multiple myeloma live longer than white patients with similar disease symptoms when both receive the same new and updated medical treatments,…

The therapy Sarclisa (isatuximab) extended survival by nearly seven months in relapsed/refractory multiple myeloma patients also given Pomalyst (pomalidomide) and dexamethasone as standard…

The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone,…

People with blood type O are significantly less likely to develop multiple myeloma, but those who do are…

Xgeva (denosumab) has been approved by the China National Medical Products Administration (NMPA) to prevent…

Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma waiting for CAR T-cells to…